From breakthrough to blockbuster: the business of biotechnology
Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major...
Gespeichert in:
| Beteiligte Personen: | , , |
|---|---|
| Weitere beteiligte Personen: | |
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
[Place of publication not identified]
Ascent Audio
2022
|
| Ausgabe: | [First edition]. |
| Schlagwörter: | |
| Links: | https://learning.oreilly.com/library/view/-/9781663720757/?ar https://learning.oreilly.com/library/view/~/9781663720757/?ar |
| Zusammenfassung: | Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. |
| Beschreibung: | Online resource; title from title details screen (O'Reilly, viewed August 30, 2022) |
| Umfang: | 1 Online-Ressource (1 audio file (07 hr., 01 min.)) |
| ISBN: | 9781663720757 1663720754 |
Internformat
MARC
| LEADER | 00000cam a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-30-ORH-082179328 | ||
| 003 | DE-627-1 | ||
| 005 | 20240228121756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221012s2022 xx |||||o 00| ||eng c | ||
| 020 | |a 9781663720757 |c electronic audio bk. |9 978-1-6637-2075-7 | ||
| 020 | |a 1663720754 |c electronic audio bk. |9 1-6637-2075-4 | ||
| 035 | |a (DE-627-1)082179328 | ||
| 035 | |a (DE-599)KEP082179328 | ||
| 035 | |a (ORHE)9781663720757 | ||
| 035 | |a (DE-627-1)082179328 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | |a 338.4/76606 |2 23/eng/20220830 | |
| 100 | 1 | |a Drakeman, Donald L. |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a From breakthrough to blockbuster |b the business of biotechnology |c Donald L. Drakeman, Lisa N. Drakeman, and Nektarios Oraiopoulos |
| 250 | |a [First edition]. | ||
| 264 | 1 | |a [Place of publication not identified] |b Ascent Audio |c 2022 | |
| 300 | |a 1 Online-Ressource (1 audio file (07 hr., 01 min.)) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online resource; title from title details screen (O'Reilly, viewed August 30, 2022) | ||
| 520 | |a Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. | ||
| 650 | 0 | |a Biotechnology industries | |
| 650 | 4 | |a Bio-industries | |
| 650 | 4 | |a Biotechnology industries | |
| 650 | 4 | |a Downloadable audio books | |
| 650 | 4 | |a Audiobooks | |
| 650 | 4 | |a Audiobooks | |
| 650 | 4 | |a Livres audio | |
| 700 | 1 | |a Ciulla, Chris Andrew |d 1975- |e ErzählerIn |4 nrt | |
| 700 | 1 | |a Drakeman, Lisa Natale |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oraiopoulos, Nektarios |e VerfasserIn |4 aut | |
| 966 | 4 | 0 | |l DE-91 |p ZDB-30-ORH |q TUM_PDA_ORH |u https://learning.oreilly.com/library/view/-/9781663720757/?ar |m X:ORHE |x Aggregator |z lizenzpflichtig |3 Volltext |
| 966 | 4 | 0 | |l DE-91 |p ZDB-30-ORH |q TUM_PDA_ORH |u https://learning.oreilly.com/library/view/~/9781663720757/?ar |m X:ORHE |x Aggregator |z lizenzpflichtig |3 Volltext |
| 912 | |a ZDB-30-ORH | ||
| 912 | |a ZDB-30-ORH | ||
| 951 | |a BO | ||
| 912 | |a ZDB-30-ORH | ||
| 049 | |a DE-91 | ||
Datensatz im Suchindex
| DE-BY-TUM_katkey | ZDB-30-ORH-082179328 |
|---|---|
| _version_ | 1821494819066740736 |
| adam_text | |
| any_adam_object | |
| author | Drakeman, Donald L. Drakeman, Lisa Natale Oraiopoulos, Nektarios |
| author2 | Ciulla, Chris Andrew 1975- |
| author2_role | nrt |
| author2_variant | c a c ca cac |
| author_facet | Drakeman, Donald L. Drakeman, Lisa Natale Oraiopoulos, Nektarios Ciulla, Chris Andrew 1975- |
| author_role | aut aut aut |
| author_sort | Drakeman, Donald L. |
| author_variant | d l d dl dld l n d ln lnd n o no |
| building | Verbundindex |
| bvnumber | localTUM |
| collection | ZDB-30-ORH |
| ctrlnum | (DE-627-1)082179328 (DE-599)KEP082179328 (ORHE)9781663720757 |
| dewey-full | 338.4/76606 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76606 |
| dewey-search | 338.4/76606 |
| dewey-sort | 3338.4 576606 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| edition | [First edition]. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03098cam a22004932 4500</leader><controlfield tag="001">ZDB-30-ORH-082179328</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20240228121756.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">221012s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781663720757</subfield><subfield code="c">electronic audio bk.</subfield><subfield code="9">978-1-6637-2075-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1663720754</subfield><subfield code="c">electronic audio bk.</subfield><subfield code="9">1-6637-2075-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)082179328</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP082179328</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ORHE)9781663720757</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)082179328</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76606</subfield><subfield code="2">23/eng/20220830</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Drakeman, Donald L.</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">From breakthrough to blockbuster</subfield><subfield code="b">the business of biotechnology</subfield><subfield code="c">Donald L. Drakeman, Lisa N. Drakeman, and Nektarios Oraiopoulos</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">[First edition].</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Place of publication not identified]</subfield><subfield code="b">Ascent Audio</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (1 audio file (07 hr., 01 min.))</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Online resource; title from title details screen (O'Reilly, viewed August 30, 2022)</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Biotechnology industries</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bio-industries</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biotechnology industries</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Downloadable audio books</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Audiobooks</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Audiobooks</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Livres audio</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ciulla, Chris Andrew</subfield><subfield code="d">1975-</subfield><subfield code="e">ErzählerIn</subfield><subfield code="4">nrt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drakeman, Lisa Natale</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oraiopoulos, Nektarios</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-91</subfield><subfield code="p">ZDB-30-ORH</subfield><subfield code="q">TUM_PDA_ORH</subfield><subfield code="u">https://learning.oreilly.com/library/view/-/9781663720757/?ar</subfield><subfield code="m">X:ORHE</subfield><subfield code="x">Aggregator</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-91</subfield><subfield code="p">ZDB-30-ORH</subfield><subfield code="q">TUM_PDA_ORH</subfield><subfield code="u">https://learning.oreilly.com/library/view/~/9781663720757/?ar</subfield><subfield code="m">X:ORHE</subfield><subfield code="x">Aggregator</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-ORH</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-ORH</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-ORH</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield></datafield></record></collection> |
| id | ZDB-30-ORH-082179328 |
| illustrated | Not Illustrated |
| indexdate | 2025-01-17T11:20:26Z |
| institution | BVB |
| isbn | 9781663720757 1663720754 |
| language | English |
| open_access_boolean | |
| owner | DE-91 DE-BY-TUM |
| owner_facet | DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (1 audio file (07 hr., 01 min.)) |
| psigel | ZDB-30-ORH TUM_PDA_ORH ZDB-30-ORH |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Ascent Audio |
| record_format | marc |
| spelling | Drakeman, Donald L. VerfasserIn aut From breakthrough to blockbuster the business of biotechnology Donald L. Drakeman, Lisa N. Drakeman, and Nektarios Oraiopoulos [First edition]. [Place of publication not identified] Ascent Audio 2022 1 Online-Ressource (1 audio file (07 hr., 01 min.)) Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Online resource; title from title details screen (O'Reilly, viewed August 30, 2022) Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Biotechnology industries Bio-industries Downloadable audio books Audiobooks Livres audio Ciulla, Chris Andrew 1975- ErzählerIn nrt Drakeman, Lisa Natale VerfasserIn aut Oraiopoulos, Nektarios VerfasserIn aut |
| spellingShingle | Drakeman, Donald L. Drakeman, Lisa Natale Oraiopoulos, Nektarios From breakthrough to blockbuster the business of biotechnology Biotechnology industries Bio-industries Downloadable audio books Audiobooks Livres audio |
| title | From breakthrough to blockbuster the business of biotechnology |
| title_auth | From breakthrough to blockbuster the business of biotechnology |
| title_exact_search | From breakthrough to blockbuster the business of biotechnology |
| title_full | From breakthrough to blockbuster the business of biotechnology Donald L. Drakeman, Lisa N. Drakeman, and Nektarios Oraiopoulos |
| title_fullStr | From breakthrough to blockbuster the business of biotechnology Donald L. Drakeman, Lisa N. Drakeman, and Nektarios Oraiopoulos |
| title_full_unstemmed | From breakthrough to blockbuster the business of biotechnology Donald L. Drakeman, Lisa N. Drakeman, and Nektarios Oraiopoulos |
| title_short | From breakthrough to blockbuster |
| title_sort | from breakthrough to blockbuster the business of biotechnology |
| title_sub | the business of biotechnology |
| topic | Biotechnology industries Bio-industries Downloadable audio books Audiobooks Livres audio |
| topic_facet | Biotechnology industries Bio-industries Downloadable audio books Audiobooks Livres audio |
| work_keys_str_mv | AT drakemandonaldl frombreakthroughtoblockbusterthebusinessofbiotechnology AT ciullachrisandrew frombreakthroughtoblockbusterthebusinessofbiotechnology AT drakemanlisanatale frombreakthroughtoblockbusterthebusinessofbiotechnology AT oraiopoulosnektarios frombreakthroughtoblockbusterthebusinessofbiotechnology |